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Frequency of and Prognostic Significance of Cardiac
Involvement at Presentation in Hereditary
Transthyretin-Derived Amyloidosis and the Value of
N-Terminal Pro-B-Type Natriuretic Peptide
Sebastiaan H.C. Klaassen, BSca,*, Jasper Tromp, MDa,b, Hans L.A. Nienhuis, MD, PhDc,
Peter van der Meer, MD, PhDa, Maarten P. van den Berg, MD, PhDa, Hans Blokzijl, MD, PhDd,
Dirk J. van Veldhuisen, MD, PhDa, and Bouke P.C. Hazenberg, MD, PhDc
The aim of this study is to assess the prevalence of cardiac involvement in hereditary
transthyretin-derived (ATTRm) amyloidosis at the time of diagnosis and to determine the
diagnostic and clinical value of N-terminal pro-B-type natriuretic peptide (NT-proBNP).
The University Medical Center Groningen is the national center of expertise for amyloi-
dosis. All consecutive patients between 1994 and 2016 with ATTRm amyloidosis were
followed prospectively. Baseline was set at the time of the first positive biopsy. All patients
underwent a standard cardiac and neurologic work-up. Cardiac involvement was defined
by otherwise unexplained left and/or right ventricular wall hypertrophy on cardiac ultra-
sound and/or advanced conduction disturbances. Seventy-seven patients had ATTRm
amyloidosis and were included in the study. The TTR V30M mutation was present in 30
patients (39%). In both the V30M and the non-V30M groups, the neurologic presentation
dominated (77% vs 51%), whereas cardiac presentation was infrequent (7% vs 15%).
Clinical work-up showed that cardiac involvement was present at baseline in 51% of all
patients irrespective of genotype and was associated with increased overall mortality
(hazard ratio 5.95, 95% confidence interval 2.12 to 16.7), independent from clinical
confounders. At a cutoff level of 125 ng/L, NT-proBNP had a sensitivity of 92% for
establishing cardiac involvement. In conclusion, irrespective of the frequent noncardiac
presentation of ATTRm amyloidosis, cardiac involvement is already present at diagnosis
in half of the patients and is associated with increased mortality. NT-proBNP is a useful
marker to determine cardiac involvement in this disease. © 2018 The Authors. Published
by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). (Am J Cardiol 2018;121:107–112)
Hereditary transthyretin-derived amyloidosis (ATTRm) is
a rare protein-folding disease.1,2 ATTRm amyloidosis usually
presents with symptoms of a length-dependent polyneuropa-
thy.At presentation, this disease usually seems to affect 1 single
organ or tissue. However, because of the systemic nature of
ATTRm amyloidosis, subtle involvement of multiple organ
systems may already be present at the time of diagnosis. Limited
data are available on the actual presence and the impact on
prognosis of cardiac involvement in patients withATTRm amy-
loidosis presenting with noncardiac phenotypes. Whereas
N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a
powerful marker to predict new-onset heart failure in the general
population,3 its role in identifying cardiac involvement in
ATTRm amyloidosis is described in only few studies.4,5 There-
fore, the objective of this study was to investigate the prevalence
of cardiac involvement at the time of diagnosis in patients
presenting with ATTRm amyloidosis and the utility of NT-
proBNP as a tool to detect cardiac involvement.
Patients and Methods
The University Medical Center Groningen is the national
center of expertise for all types of systemic and localized amy-
loidosis in The Netherlands. Patients with proven or suspected
amyloidosis are referred by different specialists, depending
on the phenotype, for further diagnostic testing and treat-
ment. All patients are followed prospectively in the Groningen
Amyloidosis Cohort since 1985. For the purpose of the present
study, data of all consecutive patients in this database between
1994 and 2016 with suspected ATTR amyloidosis were re-
viewed. Family members of patients withATTRm are routinely
referred to our center to be screened, presymptomatic, for the
presence of a TTR mutation and of amyloid.
Patients were included only when the presence of amyloid
was proven in a biopsy, subsequently typed as ATTR, and
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DNA analysis revealed a mutation in the TTR gene.6 Patient
charts were used to collect data on clinical characteristics,
laboratory measurements, and electrocardiographic and
echocardiographic measurements. Baseline was set at the time
of the first biopsy containing amyloid. Measurements were
considered to be performed at “baseline” if they took place
within a window of 1 year previously or past the date of the
positive biopsy. Patients with iatrogenic ATTR amyloidosis
caused by a domino liver transplantation of a donor with
ATTRm amyloidosis were excluded. The study conformed
to the Principles of the Declaration of Helsinki and the local
ethics committee.
Cardiac involvement was defined by the presence of struc-
tural myocardial wall abnormalities and/or conduction
disturbances.7 Structural abnormalities were defined as oth-
erwise unexplained increased left (>11 mm) or right (>6 mm)
ventricular wall thickness.8 Right ventricular involvement, a
common finding in systemic amyloidosis, was included in this
definition.9 Conduction disturbances were defined as second-
or third-degree atrioventricular block, or hemi- or complete
bundle branch block. Low-voltage electrocardiogram was
defined by the Sokolow-Lyon index.10
The reason for performing the biopsy was retrieved and
classified as the presenting phenotype. Furthermore, as part
of specialized care, patients underwent cardiac investiga-
tions such as echocardiography, electrocardiography,
ambulatory 24-hour electrocardiographic monitoring, and mea-
surement of serum NT-proBNP using a standard immunoassay
(Elecsys 2010; Roche Diagnostics),11 and usually patients were
referred to the cardiologist of the team. When the left ven-
tricular ejection fraction had been measured as a range, the
median value of that range was used for analysis. Neuro-
physiologic tests were performed to detect polyneuropathy,
autonomic neuropathy (Ewing tests12), or thin fiber neuropa-
thy. Vitreous opacities were documented by ophthalmologic
examination. During follow-up, these tests were repeated when
deemed necessary by the attending physician.
Data are presented as medians with interquartile ranges,
means with standard deviations, or percentages depending
on the variable. For testing significance of differences
between the 2 groups, the χ2 test, the Kruskal-Wallis
equality-of-populations rank test, or the 1-way analysis of
variance was used where appropriate. The Pearson test was
used for the correlation analyses. Kaplan-Meier curves
were used for survival and analyzed using the log-rank test.
Univariate and multivariate Cox proportional hazard regres-
sion models were used to calculate the hazard ratio of
cardiac involvement on mortality. To determine the role of
the biomarker NT-proBNP in the discrimination of patients
with or without cardiac involvement, a receiver operating
characteristic (ROC) curve was constructed. A 2-tailed p
value of <0.05 was considered to be statistically significant.
Analyses were conducted using STATA version 13 (StataCorp
LP, College Station, TX).
Results
In total, 155 patients with proven or suspected ATTR were
referred to our center between 1994 and 2016. Thirty-five pa-
tients were excluded based on a negative biopsy, 12 patients
were excluded based on missing biopsy data, 20 patients were
excluded because a TTR gene mutation was lacking (wild-
type variant), 10 patients were excluded because no sufficient
clinical data were available, and 1 patient was excluded because
of iatrogenic amyloidosis caused by domino liver transplan-
tation. The remaining 77 patients were included for further
analysis, including the 29 patients who underwent a liver trans-
plantation during follow-up. In 30 of the 77 patients, the TTR
V30M genotype was present, and the non-V30M group con-
sisted of 47 patients. Nine different TTR gene mutations were
present in the non-V30M group: Y114C (N = 23), V71A
(N = 8), G47E (N = 7), G89K (N = 3), V122I (N = 2), V94A
(N = 1), A45G (N = 1), A36P (N = 1), and S23N (N = 1).
Baseline characteristics are provided in Table 1. Symp-
toms of a peripheral neuropathy were the most frequent reason
for performing the biopsy in both the V30M group (77%) and
the non-V30M group (51%). Symptoms of a cardiomyopa-
thy were much less frequently the reason for a biopsy in both
the V30M (7%) and the non-V30M group (15%). During di-
agnostic work-up at baseline, peripheral neuropathy (78%)
and autonomic dysfunction (57%) were frequently present.
Symptoms of heart failure were absent in most patients.
At baseline, 39 (51%) patients met the criteria of cardiac
involvement, and this did not differ between the 2 genotype
groups. In the Supplement Table S1 the basline data is clas-
sified by cardiac involvement (Table S1) and also classified
bycardiac reason for the biopsy (Table S2). All 9 (12%) pa-
tients with a cardiac reason for the biopsy had cardiac
involvement. Of the remaining 68 (88%) patients with a non-
cardiac reason for biopsy, 30 (44%) patients had cardiac
involvement, including 2 of 8 patients who were screened
because of family history. Supplementary Table S3 shows the
results of logistic regression on cardiac involvement.
In Figure 1A, the serum levels of NT-proBNP and age at
diagnosis are depicted for males and females. A correlation
was present in both males and females. Figure 1B depicts the
NT-proBNP serum levels and age at diagnosis for the V30M
and non-V30M groups. The regression lines of both V30M
and non-V30M are shown and seem to run parallel and nearby
the 97.5% upper limit of controls.13 Figure 1C depicts the NT-
proBNP serum levels and age at diagnosis for patients with
and without cardiac involvement. Levels were higher in the
patients with cardiac involvement (p < 0.001).
In Figure 2, the ROC curve for NT-proBNP for cardiac
involvement is shown; the area under the curve was 0.905.
Based on this ROC curve, 2 cutoff levels were set: one with
high sensitivity and another with high specificity. The sen-
sitive cutoff level of 164 ng/L had negative predictive value
87.5%. The specific cutoff level of 365 ng/L had a positive
predictive value of 93%. The 2 chosen cutoff levels are shown
in Figure 1C. The literature-based cutoff level of 125 ng/L14
yielded a sensitivity of 92% and a specificity of 65%.
Median follow-up was 6 years, and in this period, 33 (43%)
patients died. Mean age at death was 61 years. The Kaplan-
Meier survival curve (Figure 3A) shows that no significant
difference in mortality was observed between the V30M group
and the non-V30M group. Figure 3B shows that patients with
cardiac involvement at baseline had reduced survival during
follow-up compared with patients without cardiac involve-
ment. Patients with cardiac involvement had a 50% all-
cause mortality of 4 years, whereas the 50% all-cause mortality
was not reached in the patients without cardiac involvement.
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Supplementary Figure S1 shows the survival curves for pa-
tients with high and low NT-proBNP. A Cox survival analysis
was performed to determine the hazard ratio of cardiac in-
volvement on mortality (Table 2). Even when adjusted for
age, sex, systolic pressure, renal function, and V30M geno-
type, cardiac involvement remained associated with increased
mortality (model 2 in Table 2).
Discussion
This study shows that cardiac involvement is present in
half of the patients presenting with ATTRm amyloidosis, re-
gardless of initial clinical presentation and genotype (V30M
vs non-V30M). Furthermore, the results indicate that cardiac
involvement is associated with adverse outcomes, indepen-
dent of other clinical characteristics. Lastly, NT-proBNP
appears to be a useful marker in determining cardiac involve-
ment in patients presenting with ATTRm amyloidosis.
Although ATTRm amyloidosis is a heterogeneous disease,
most TTR mutations induce neurologic symptoms. It was there-
fore initially described as familial amyloid polyneuropathy.15
However, Rapezzi et al described a mixed presentation of both
neurologic and cardiac symptoms in their Italian cohort of
patients with ATTR amyloidosis comprising a sizeable number
of mutations.7 Because of these findings, we aimed to inves-
tigate the presence of cardiac involvement in our population
of Dutch patients with ATTRm amyloidosis subdivided in
V30M and non-V30M TTR genotypes.
Table 1
Clinical characteristics at baseline
Variable Total (n = 77) Non-V30M (n = 47) V30M (n = 30) p
Age at diagnosis (years ± SD) 54 ± 14 50.5 ± 11.4 56.3 ± 16.1 0.067
Age at death (years ± SD) 61 ± 10 58.4 ± 9.5 65.0 ± 9.2 0.067
Men 55.8% 46.8% 70% 0.024
Reason for a biopsy, signs of:
Peripheral neuropathy 61.0% 51.1% 76.7% 0.025
Autonomic dysfunction 2.6% 2.1% 3.3% 0.750
Cardiomyopathy 11.7% 14.9% 6.7% 0.270
Ocular opacities 7.8% 10.6% 3.3% 0.240
CTS 3.9% 6.4% 0.0 0.160
Family history 10.0% 12.8% 6.7% 0.390
Miscellaneous 3.0% 2.1% 3.3% 0.746
Clinical status
Peripheral neuropathy 77.6% 72.3% 86.3% 0.160
Autonomic dysfunction 57.1% 59.6% 53.6% 0.590
Gastro-intestinal complaints 32.0% 34.0% 28.6% 0.620
Cardiac involvement 51.0% 49.0% 53.0% 0.707
Ocular opacities 22.0% 31.9% 6.7% 0.009
CTS 19.7% 23.4% 13.8% 0.310
NYHA class 0.250
I 80.5% 87.2% 72.4% 0.063
II 13.0% 8.5% 20.7% 0.144
III 5.2% 4.3% 6.9% 0.642
IV 0 0 0 -
Blood pressure (mmHg)
Peak Systolic 130.0 (115.0, 145.0) 130.0 (110.0, 140.0) 140.0 (120.0, 150.0) 0.043
End Diastolic 80.0 (70.0, 88.0) 80.0 (70.0, 88.0) 80.0 (70.0, 87.5) 0.900
Electrocardiographic findings
Atrial fibrillation 2.8% 2.2% 3.8% 0.680
Low voltage QRS complexes 4.2% 4.3% 3.8% 0.920
Bundle branch block 13.9% 13.0% 15.4% 0.780
1st degree AV-block 11.7% 8.5% 16.6% 0.190
2nd/3rd degree AV-block 0 0 0 -
Echocardiogram findings
Septum wall thickness (mm) 11.0 (9.0, 13.0) 11.0 (9.0, 13.0) 11.0 (10.0, 14.0) 0.310
Left posterior wall thickness (mm) 10.0 (8.0, 12.0) 10.0 (8.4, 12.0) 9.0 (8.0, 12.0) 0.430
Right ventricular wall thickness (mm) 5.0 (4.0, 6.5) 5.0 (4.0, 6.0) 5.0 (4.0, 7.0) 0.820
LVEF (%) 60 (60, 60) 60.0 (60.0, 60.0) 60.0 (56.0, 60.0) 0.320
Laboratory findings
NT-proBNP (ng/L) 202 (78, 646) 177 (67, 677) 210 (117, 595) 0.390
Creatinine (µmol/L) 83 (73, 93) 80 (66, 93) 85 (81, 94) 0.340
eGFR (ml/min * 1.73 m2) 80.0 (70.0, 104.0) 79 (66.0, 97.0) 82.0 (74.0, 110.0) 0.140
Data are presented as medians with interquartile ranges, means with standard deviations, or percentages depending on the nature of the variable. CTS = carpal
tunnel syndrome; eGFR = estimated glomerular filtration rate; NYHA = New York Heart Association functional classification of heart failure; LVEF = left
ventricular ejection fraction.
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Length-dependent peripheral neuropathy is typically seen
in patients with ATTR amyloidosis and is characterized by
numbness, spontaneous pain, muscle weakness, and atrophy.
Similar to autonomic dysfunction, these peripheral neuro-
pathic characteristics all contribute to a decreased performance
and impaired exercise tolerance.16 Exercise intolerance can
already be explained by these neurologic limitations; however,
one of the hallmarks of cardiac disease is also a decreased
exercise tolerance.17 Irrespective of phenotype, patients with
ATTR amyloidosis do not challenge their exercise capacity
and therefore cardiac symptoms may be camouflaged by con-
current neurologic symptoms, making cardiac involvement
of amyloidosis a challenging feature to diagnose. More specu-
lative is that autonomic dysfunction may cause lower filling
pressures in the heart because of venous blood pooling, thereby
masking underlying cardiac abnormalities.18
In only a small proportion of our population the reason
for a biopsy was symptoms suggestive of a cardiomyopa-
thy, their presenting symptoms were shortness of breath,
edema, and/or signs of congestion. Typical amyloidosis-
related electrocardiogram findings, that is, low voltages and
advanced atrioventricular blocks, were not prominent, and
evident echocardiographic abnormalities were also absent in
most of these patients at presentation.19 Of note, the criteria
of cardiac involvement used in this study were a little less
stringent than those used by Rapezzi et al.7 In our study, cardiac
hypertrophy was defined as an interventricular septum or pos-
terior wall thickness of >11 mm or when right ventricular
hypertrophy (>6 mm) was present, whereas in the study of
Rapezzi et al right ventricular dimensions were not in-
cluded in the definition, and a thickness of 13 mm or greater
was used for the left ventricle. In our opinion, especially the
wall thickness cutoff criteria of our study are more in line
with regard to the current echocardiography guidelines.8 Ir-
respective of the noncardiac clinical presentation or the
genotype, the heart was already affected at diagnosis in about
half of our patients. If myocardial radiotracer uptake on bone
scintigraphy had been used to detect cardiac involvement in
this study, even more patients might have been identified.20
Figure 1. Log-transformed serum NT-proBNP values and age at diagnosis.
(A) Males (filled circles) and females (open diamonds). Linear regression
lines for males (solid line) and females (dashed line).
(B) V30M (filled circles) and non-V30M (open diamonds) genotypes.
Linear regression lines for V30M (solid line) and non-V30M (dashed line)
genotypes. Inserted is the 97.5% upper limit (UL) of controls (dashed line).
(C) Patients with cardiac involvement (filled circles) and patients without
cardiac involvement (open diamonds). The 2 horizontal lines are the chosen
cutoff values of NT-proBNP, 164 ng/L and 365 ng/L, respectively.
Figure 2. ROC curve of serum NT-proBNP for cardiac involvement. The
2 chosen cutoff values are shown with arrows: 164 ng/L, with sensitivity
92% and specificity 76% (solid arrow), and 365 ng/L, with sensitivity 92%
and specificity 68% (dashed arrow).
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In recent years, the natriuretic peptide BNP and NT-
proBNP biomarkers became available in heart failure. These
natriuretic peptides predict outcome not only in the general
population,21 but also in patients with heart failure.22 Several
studies described the prognostic value of NT-proBNP on
outcome in patients with ATTR amyloidosis, including a recent
study using the THAOS Registry, but few studies described
the diagnostic value of NT-proBNP of cardiac involvement
in these patients.4,5,23,24 The NT-proBNP levels did not differ
in the 2 genotype groups (V30M vs non-V30M), and the NT-
proBNP levels correlated with age for both males and females
in both genotype groups. This age-related increase of NT-
proBNP in our study group was at a higher level than the well-
known physiological age-dependent increase of NT-proBNP.13
It therefore appears that cardiac involvement in ATTRm amy-
loidosis is not so much determined by genotype but by the
age at disease onset.
The current findings emphasize the importance of NT-
proBNP measurements in patients with ATTR amyloidosis,
because increased serum levels of NT-proBNP reveal cardiac
involvement.14 In as many as half of our patients, cardiac in-
volvement could be demonstrated at presentation, and our
results indicate that NT-proBNP is a good diagnostic tool for
medical specialists other than cardiologists to detect cardiac
involvement.
Recognition of cardiac involvement is of great impor-
tance in the proper treatment of ATTR amyloidosis. This study
shows that cardiac involvement predicts overall survival and
confirms previous studies.23,25 In the last few years, TTR
tetramer-stabilizing treatment for ATTR amyloidosis became
available for polyneuropathy.26 A similar randomized clini-
cal trial in patients with cardiomyopathy as disease
manifestation will be completed in 2018.27 Early identifica-
tion of cardiac involvement is therefore mandatory to treat
amyloidosis adequately, because late-stage cardiomyopathy
probably will benefit less from treatment.16
Limitations of our study are the relatively small popula-
tion size and small number of mutations. Loss of renal function
and cardiac rhythm abnormalities may cause elevated NT-
proBNP levels, but severe renal function loss was not present,
whereas only 2 patients had atrial fibrillation. Because of the
long study period of more than 20 years, it was not possible
to use more recent and advanced techniques to detect cardiac
involvement, such as bisphosphonate scintigraphy, mag-
netic resonance imaging T1-myomapping, and strain
measurement and speckle tracking by echocardiography.
In conclusion, cardiac involvement in ATTRm amyloido-
sis is not limited to certain genotypes or a specific clinical
presentation and is of great influence on the overall sur-
vival. Measuring the cardiac biomarker NT-proBNP is useful
in the early evaluation of cardiac involvement in ATTR
amyloidosis.
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